| [1] |
Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target[J]. Exp Hematol Oncol, 2023,12(1):84.
|
| [2] |
Park J S, Gazzaniga F S, Wu M, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance[J]. Nature, 2023,617(7960):377-385.
|
| [3] |
Yilmaz B, Fuhrer T, Morgenthaler D, et al. Plasticity of the adult human small intestinal stoma microbiota[J]. Cell Host Microbe, 2022,30(12):1773-1787.
|
| [4] |
Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease[J]. Front Cell Infect Microbiol, 2021,11:625913.
|
| [5] |
Liu S, Yang X. Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer[J]. Frontiers In Cellular And Infection Microbiology, 2023,13:1140126.
|
| [6] |
Hsu C L, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023,21(11):719-733.
|
| [7] |
Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature[J]. Int J Mol Sci, 2019,20(2):395.
|
| [8] |
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020,72(3):558-577.
|
| [9] |
Guan H, Zhang X, Kuang M, et al. The gut-liver axis in immune remodeling of hepatic cirrhosis[J]. Front Immunol, 2022,13:946628.
|
| [10] |
Moon A M, Singal A G, Tapper E B. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol, 2020,18(12):2650-2666.
|
| [11] |
Lee N Y, Suk K T. The role of the gut microbiome in liver cirrhosis treatment[J]. Int J Mol Sci, 2020,22(1):199.
|
| [12] |
Sole C, Guilly S, Da S K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis[J]. Gastroenterology, 2021,160(1):206-218.
|
| [13] |
Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles[J]. Drugs, 2019,79(Suppl 1):5-9.
|
| [14] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy[J]. J Hepatol, 2022,77(3):807-824.
|
| [15] |
Rose C F, Amodio P, Bajaj J S, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy[J]. J Hepatol, 2020,73(6):1526-1547.
|
| [16] |
Llopis M, Cassard A M, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016,65(5):830-839.
|
| [17] |
Bajaj J S, Salzman N H, Acharya C, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial[J]. Hepatology, 2019,70(5):1690-1703.
|
| [18] |
Bloom P P, Tapper E B, Young V B, et al. Microbiome therapeutics for hepatic encephalopathy[J]. J Hepatol, 2021,75(6):1452-1464.
|
| [19] |
Bajaj J S, Salzman N, Acharya C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis[J]. JCI Insight, 2019,4(24):e133410.
|
| [20] |
Bajaj J S, Fagan A, Gavis E A, et al. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis[J]. Gastroenterology, 2019,156(6):1921-1923.
|
| [21] |
Sydor S, Best J, Messerschmidt I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC[J]. Clin Transl Gastroenterol, 2020,11(3):e00131.
|
| [22] |
Bataller R, Arab J P, Shah V H. Alcohol-associated hepatitis[J]. N Engl J Med, 2022,387(26):2436-2448.
|
| [23] |
Shasthry S M. Fecal microbiota transplantation in alcohol related liver diseases[J]. Clin Mol Hepatol, 2020,26(3):294-301.
|
| [24] |
Philips C A, Pande A, Shasthry S M, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study[J]. Clin Gastroenterol Hepatol, 2017,15(4):600-602.
|
| [25] |
Jung J H, Kim S E, Suk K T, et al. Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota[J]. Front Med (Lausanne), 2022,9:913842.
|
| [26] |
Chi X, Pan C Q, Liu S, et al. Regulating intestinal microbiota in the prevention and treatment of alcohol-related liver disease[J]. Can J Gastroenterol Hepatol, 2020,2020:6629196.
|
| [27] |
Philips C A, Ahamed R, Rajesh S, et al. Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala[J]. Gastroenterol Rep (Oxf), 2022,10:goac074.
|
| [28] |
Zhang W, Xu X, Cai L, et al. Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma[J]. Sci Rep, 2023,13(1):7797.
|
| [29] |
Anwanwan D, Singh S K, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020,1873(1):188314.
|
| [30] |
Zhou A, Tang L, Zeng S, et al. Gut microbiota: a new piece in understanding hepatocarcinogenesis[J]. Cancer Lett, 2020,474:15-22.
|
| [31] |
Jiang J W, Chen X H, Ren Z, et al. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis[J]. Hepatobiliary Pancreat Dis Int, 2019,18(1):19-27.
|
| [32] |
Guillot N, Romeo B, Manesh S S, et al. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality[J]. Trends Mol Med, 2023,29(11):897-911.
|
| [33] |
Routy B, Lenehan J G, Miller W J, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial[J]. Nat Med, 2023,29(8):2121-2132.
|
| [34] |
Wu W, Yu J. Microbiota-based biomarkers and therapeutics for cancer management[J]. Nat Rev Gastroenterol Hepatol, 2024,21(2):72-73.
|
| [35] |
Ross J A, Komoda K, Pal S, et al. Infectious complications of immune checkpoint inhibitors in solid organ malignancies[J]. Cancer Med, 2022,11(1):21-27.
|
| [36] |
Fasanello M K, Robillard K T, Boland P M, et al. Use of fecal microbial transplantation for immune checkpoint inhibitor colitis[J]. ACG Case Rep J, 2020,7(4):e00360.
|
| [37] |
Simpson R C, Shanahan E R, Scolyer R A, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2023,20(10):697-715.
|
